down arrow

KalVista Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4834971032
USD
14.90
0.14 (0.95%)

Feb 06

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

14.4815.07

52 Week

8.8419.00
Valuation
Technical
Day's Volume

CASH

1.14 M

Shareholding (Sep 2025)

FII

9.93%

Held by 60 FIIs

DII

37.53%

Held by 29 DIIs

Promoter

30.31%

How big is KalVista Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, KalVista Pharmaceuticals, Inc. has a market capitalization of 603.80 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -175.87 million over the latest four quarters. As of Apr 24, the company reported shareholder's funds of 206.58 million and total assets of 235.40 million.

Market Cap: As of Jun 18, KalVista Pharmaceuticals, Inc. has a market capitalization of 603.80 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, KalVista Pharmaceuticals, Inc. reported net sales of 0.00 million and a net profit of -175.87 million.<BR><BR>Balance Sheet Snapshot: As of Apr 24, the company reported shareholder's funds of 206.58 million and total assets of 235.40 million.

View full answer

What does KalVista Pharmaceuticals, Inc. do?

22-Jun-2025

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in small molecule protease inhibitors. It has a market cap of $603.80 million and reported a net profit loss of $49 million as of January 2025.

Overview: <BR>KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -49 Million (Quarterly Results - Jan 2025) <BR>Market cap: USD 603.80 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -121.18% <BR>Price to Book: 4.16<BR><BR>Contact Details: <BR>Address: 55 Cambridge Pkwy Ste 901E, CAMBRIDGE MA: 02142-1234 <BR>Tel: 1 857 9990075 <BR>Website: http://www.kalvista.com/

View full answer

Who are in the management team of KalVista Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of KalVista Pharmaceuticals, Inc. includes Dr. Martin Edwards (Independent Chairman), Mr. Thomas Crockett (CEO), and several independent directors: Dr. Albert Cha, Mr. Arnold Oronsky, Dr. Brian Pereira, Mr. Daniel Soland, and Mr. Edward Unkart. They oversee the company's strategic direction and operations.

As of March 2022, the management team of KalVista Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Martin Edwards, Independent Chairman of the Board<BR>- Mr. Thomas Crockett, Chief Executive Officer and Director<BR>- Dr. Albert Cha, Independent Director<BR>- Mr. Arnold Oronsky, Independent Director<BR>- Dr. Brian Pereira, Independent Director<BR>- Mr. Daniel Soland, Independent Director<BR>- Mr. Edward Unkart, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

View full answer

Is KalVista Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of September 11, 2025, KalVista Pharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics, including a Price to Book Value of 4.92 and an ROE of -121.18%, while its performance has underperformed the S&P 500 despite a YTD return of 63.87%.

As of 11 September 2025, the valuation grade for KalVista Pharmaceuticals, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company appears to be overvalued given its significant negative metrics, including a Price to Book Value of 4.92 and an ROE of -121.18%. Additionally, the EV to EBIT and EV to EBITDA ratios are both negative, at -3.10 and -3.12 respectively, which further underscores the company's financial struggles.<BR><BR>In comparison to its peers, KalVista's valuation ratios are concerning; for instance, Icosavax, Inc. has a P/E of -7.9922, while Nurix Therapeutics, Inc. shows a P/E of -3.5769, both indicating similar risk profiles. In contrast, SIGA Technologies, Inc. stands out with a more attractive P/E of 7.5458. Notably, while KalVista has shown a YTD return of 63.87%, it has underperformed against the S&P 500's return of 12.22%, and its 3-year return of -7.40% starkly contrasts with the S&P 500's 70.41%. This performance reinforces the view that the stock may be overvalued in its current state.

View full answer

Is KalVista Pharmaceuticals, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, KalVista Pharmaceuticals, Inc. exhibits a neutral technical trend with mixed signals, showing mildly bearish MACD and Bollinger Bands on both weekly and monthly charts, while daily moving averages remain mildly bullish, indicating a lack of strong momentum.

As of 10 October 2025, the technical trend for KalVista Pharmaceuticals, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different indicators. The MACD shows a mildly bearish signal on the weekly timeframe, while it remains bullish on the monthly timeframe. The Bollinger Bands indicate bearish conditions on both weekly and monthly charts. Moving averages are mildly bullish on the daily timeframe, but the KST and Dow Theory show mildly bearish signals on the weekly and monthly timeframes. Overall, the indicators suggest a lack of strong momentum in either direction. Multi-period return data is not available for comparison with the S&P 500.

View full answer

Compare KalVista Pharmaceuticals, Inc. with Similar Stocks

Oric Pharmaceuticals, Inc.Arbutus Biopharma Corp.Coherus BioSciences, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 804 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.10

stock-summary
Return on Equity

-1,227.74%

stock-summary
Price to Book

47.31

Revenue and Profits:
Net Sales:
14 Million
(Quarterly Results - Sep 2025)
Net Profit:
-49 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.27%
0%
24.27%
6 Months
57.84%
0%
57.84%
1 Year
23.75%
0%
23.75%
2 Years
50.35%
0%
50.35%
3 Years
78.44%
0%
78.44%
4 Years
-48.44%
0%
-48.44%
5 Years
30.82%
0%
30.82%

KalVista Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-221.42%
EBIT to Interest (avg)
-87.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.18
Sales to Capital Employed (avg)
0.03
Tax Ratio
1.88%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.92
EV to EBIT
-3.10
EV to EBITDA
-3.12
EV to Capital Employed
-98.50
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-121.18%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 35 Schemes (22.23%)

Foreign Institutions

Held by 60 Foreign Institutions (9.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by KalVista Pharmaceuticals, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is -44.87% vs -36.28% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-192.10",
          "val2": "-148.10",
          "chgp": "-29.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-183.40",
          "val2": "-126.60",
          "chgp": "-44.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Apr'25stock-summary

Apr'25
Apr'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-192.10
-148.10
-29.71%
Interest
5.80
0.00
Exceptional Items
-1.80
0.00
Consolidate Net Profit
-183.40
-126.60
-44.87%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2025 is -44.87% vs -36.28% in Apr 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About KalVista Pharmaceuticals, Inc. stock-summary
stock-summary
KalVista Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Company Coordinates stock-summary
Company Details
55 Cambridge Pkwy Ste 901E , CAMBRIDGE MA : 02142-1234
stock-summary
Tel: 1 857 9990075
stock-summary
http://www.kalvista.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."